Literature DB >> 26937141

Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation.

Yong-Heng Sui1, Wen-Jing Luo1, Qin-Yu Xu1, Jing Hua1.   

Abstract

AIM: To investigate the effect of different dietary fatty acids on hepatic inflammasome activation.
METHODS: Wild-type C57BL/6 mice were fed either a high-fat diet or polyunsaturated fatty acid (PUFA)-enriched diet. Primary hepatocytes were treated with either saturated fatty acids (SFAs) or PUFAs as well as combined with lipopolysaccharide (LPS). The expression of NOD-like receptor protein 3 (NLRP3) inflammasome, peroxisome proliferator-activated receptor-γ and nuclear factor-kappa B (NF-κB) was determined by real-time PCR and Western blot. The activity of Caspase-1 and interleukine-1β production were measured.
RESULTS: High-fat diet-induced hepatic steatosis was sufficient to induce and activate hepatic NLRP3 inflammasome. SFA palmitic acid (PA) directly activated NLRP3 inflammasome and increased sensitization to LPS-induced inflammasome activation in hepatocytes. In contrast, PUFA docosahexaenoic acid (DHA) had the potential to inhibit NLRP3 inflammasome expression in hepatocytes and partly abolished LPS-induced NLRP3 inflammasome activation. Furthermore, a high-fat diet increased but PUFA-enriched diet decreased sensitization to LPS-induced hepatic NLRP3 inflammasome activation in vivo. Moreover, PA increased but DHA decreased phosphorylated NF-κB p65 protein expression in hepatocytes.
CONCLUSION: Hepatic NLRP3 inflammasome activation played an important role in the development of non-alcoholic fatty liver disease. Dietary SFAs and PUFAs oppositely regulated the activity of NLRP3 inflammasome through direct activation or inhibition of NF-κB.

Entities:  

Keywords:  NOD-like receptor protein 3 inflammasome; Non-alcoholic fatty liver disease; Nuclear factor-kappa B; Polyunsaturated fatty acids; Saturated fatty acids

Mesh:

Substances:

Year:  2016        PMID: 26937141      PMCID: PMC4768199          DOI: 10.3748/wjg.v22.i8.2533

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells.

Authors:  Timea Csak; Michal Ganz; Justin Pespisa; Karen Kodys; Angela Dolganiuc; Gyongyi Szabo
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

2.  A role for mitochondria in NLRP3 inflammasome activation.

Authors:  Rongbin Zhou; Amir S Yazdi; Philippe Menu; Jürg Tschopp
Journal:  Nature       Date:  2010-12-01       Impact factor: 49.962

3.  Dietary saturated fatty acids prime the NLRP3 inflammasome via TLR4 in dendritic cells-implications for diet-induced insulin resistance.

Authors:  Clare M Reynolds; Fiona C McGillicuddy; Karen A Harford; Orla M Finucane; Kingston H G Mills; Helen M Roche
Journal:  Mol Nutr Food Res       Date:  2012-06-15       Impact factor: 5.914

4.  Inflammasome is a central player in the induction of obesity and insulin resistance.

Authors:  Rinke Stienstra; Janna A van Diepen; Cees J Tack; Md Hasan Zaki; Frank L van de Veerdonk; Deshani Perera; Geoffrey A Neale; Guido J Hooiveld; Anneke Hijmans; Irene Vroegrijk; Sjoerd van den Berg; Johannes Romijn; Patrick C N Rensen; Leo A B Joosten; Mihai G Netea; Thirumala-Devi Kanneganti
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

Review 5.  Inflammasomes in liver diseases.

Authors:  Gyongyi Szabo; Timea Csak
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

6.  Endoplasmic reticulum stress is sufficient for the induction of IL-1β production via activation of the NF-κB and inflammasome pathways.

Authors:  Sena Kim; Yeonsoo Joe; Sun Oh Jeong; Min Zheng; Sung Hoon Back; Sang Won Park; Stefan W Ryter; Hun Taeg Chung
Journal:  Innate Immun       Date:  2013-11-11       Impact factor: 2.680

7.  Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis.

Authors:  I Tavares de Almeida; H Cortez-Pinto; G Fidalgo; D Rodrigues; M E Camilo
Journal:  Clin Nutr       Date:  2002-06       Impact factor: 7.324

8.  Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model.

Authors:  Hiroshi Kudo; Terumi Takahara; Yutaka Yata; Kengo Kawai; Wei Zhang; Toshiro Sugiyama
Journal:  J Hepatol       Date:  2009-05-03       Impact factor: 25.083

9.  Elevated endotoxin levels in non-alcoholic fatty liver disease.

Authors:  Alison L Harte; Nancy F da Silva; Steven J Creely; Kirsty C McGee; Thomas Billyard; Elham M Youssef-Elabd; Gyanendra Tripathi; Esmat Ashour; Mohga S Abdalla; Hayat M Sharada; Ashraf I Amin; Alastair D Burt; Sudhesh Kumar; Christopher P Day; Philip G McTernan
Journal:  J Inflamm (Lond)       Date:  2010-03-30       Impact factor: 4.981

10.  Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice.

Authors:  Kouichi Miura; Ling Yang; Nico van Rooijen; David A Brenner; Hirohide Ohnishi; Ekihiro Seki
Journal:  Hepatology       Date:  2013-02       Impact factor: 17.425

View more
  22 in total

1.  An Orally Available NLRP3 Inflammasome Inhibitor Prevents Western Diet-Induced Cardiac Dysfunction in Mice.

Authors:  Salvatore Carbone; Adolfo G Mauro; Andrea Prestamburgo; Matthew S Halquist; Pratyush Narayan; Nicola Potere; Eleonora Mezzaroma; Benjamin W Van Tassell; Antonio Abbate; Stefano Toldo
Journal:  J Cardiovasc Pharmacol       Date:  2018-12       Impact factor: 3.105

Review 2.  Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet.

Authors:  Zeinab Mokhtari; Deanna L Gibson; Azita Hekmatdoost
Journal:  Adv Nutr       Date:  2017-03-15       Impact factor: 8.701

Review 3.  The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity.

Authors:  Stavros P Papadakos; Nikolaos Dedes; Elias Kouroumalis; Stamatios Theocharis
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

4.  Role of dietary fatty acids in liver injury caused by vinyl chloride metabolites in mice.

Authors:  Lisanne C Anders; Heegook Yeo; Brenna R Kaelin; Anna L Lang; Adrienne M Bushau; Amanda N Douglas; Matt Cave; Gavin E Arteel; Craig J McClain; Juliane I Beier
Journal:  Toxicol Appl Pharmacol       Date:  2016-09-28       Impact factor: 4.219

5.  Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation.

Authors:  Cory Iverson; Andrew Bacong; Sha Liu; Scott Baumgartner; Torbjörn Lundström; Jan Oscarsson; Jeffrey N Miner
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

6.  Interleukin-18 mediates cardiac dysfunction induced by western diet independent of obesity and hyperglycemia in the mouse.

Authors:  S Carbone; P J H Lee; A G Mauro; E Mezzaroma; R Buzzetti; B Van Tassell; A Abbate; S Toldo
Journal:  Nutr Diabetes       Date:  2017-04-10       Impact factor: 5.097

7.  Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease.

Authors:  Wenjing Luo; Qinyu Xu; Qi Wang; Huimin Wu; Jing Hua
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

8.  The Potential Effect of Chinese Herbal Formula Hongqijiangzhi Fang in Improving NAFLD: Focusing on NLRP3 Inflammasome and Gut Microbiota.

Authors:  Shu Liang; Yupei Zhang; Yuanjun Deng; Yifang He; Yinji Liang; Zien Liang; Yanning Chen; Kairui Tang; Runsen Chen; Qinhe Yang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-21       Impact factor: 2.629

Review 9.  NLRP3 Inflammasome Activation in Adipose Tissues and Its Implications on Metabolic Diseases.

Authors:  Kelvin Ka-Lok Wu; Samson Wing-Ming Cheung; Kenneth King-Yip Cheng
Journal:  Int J Mol Sci       Date:  2020-06-11       Impact factor: 5.923

Review 10.  Lipidomics in non-alcoholic fatty liver disease.

Authors:  Sofia Kartsoli; Christina E Kostara; Vasilis Tsimihodimos; Eleni T Bairaktari; Dimitrios K Christodoulou
Journal:  World J Hepatol       Date:  2020-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.